Search 

PHASTAR is a specialist biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents. PHASTAR is also currently in the process of setting up an office in Shangai, China. 

PhysioCue is digital health and therapy device development company, has developed a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.

Phyteau is developing an innovative, new class of therapeutics for diabetes, obesity, related conditions like NAFLD, NASH and prediabetes, and weight-loss. Unlike many drugs in the market today, our therapeutics are completely safe, and free of adverse side-effects.

Phyteau’s new incretin-based approach activates the body’s natural metabolic system
by triggering specialized enteroendocrine cells in the lining of the intestines to release
therapeutic levels of key hormones, including GLP-1, PYY and CCK. These boosted hormones:

1) signal insulin release,
2) reduce blood sugar levels and peaks, and HbA1c,
3) reduce appetite, food intake and weight, increase satiety,
4) slows gastric emptying and intestinal motility,
5) improve metabolism and fat thermogenesis,
6) reduce liver fat and fibrosis,
7) protect against many age-related functional declines and conditions, and
8) provide restorative and protective benefits to the cardiovascular and nervous systems and major organs

The result is safe and affordable first-line treatments that provide a powerful tool for blood sugar control, weight-loss and improving metabolism. Our technology, developed at Caltech, UCLA and Cedars Sinai Medical Center, has 3 patents awarded, 5 more pending, with more planned.

Phyteau’s deep technology platform and portfolio of agents allows us to address growing unmet global needs in a variety of markets. We have 3 pharmaceutical products in development as well as breakthrough medical and functional food products and other consumer health & nutrition products.